A cross-sectional study revealed a significant reduction in the intensity of pelvic pain among patients undergoing Letrozole treatment. Researchers investigated the efficacy of aromatase inhibitor in alleviating chronic pelvic pain related to endometriosis. Overall, 60 volunteers (mean age: 30.9 years) diagnosed with endometriosis were enrolled, including those with previous treatment history and varying levels of improvement.

The data collected was assessed utilizing Statistical Package for the Social Sciences (SPSS) version 24.0. To diagnose and score endometriosis, an initial diagnostic laparoscopy was performed before initiating the treatment.  The patients were then administered vitamin D (1000 IU), Progestin norethisterone acetate 5 mg, Calcium citrate 1000 mg, Celbex 200 mg three times a day, and Letrozole 2.5 mg orally for a duration of 6 months.

Among the 60 patients, 26 (43.3%) experienced dysmenorrhea. Of the total participants, 43 (71.6%) were nulliparous. The initial mean visual analogue scale (VAS) score at the beginning of the therapy was 7.12. After one month of treatment, the VAS score decreased to 6.8, and at the end of six months, it further dropped to 3.3. Thus, Letrozole shows great potential in the treatment of endometriosis-linked pelvic discomfort, providing much-needed relief for patients suffering from this condition.